|
|
Enhancing Patient Care for CAR T-Cell Therapy in NHL: Comprehensive Solutions for Your Community
In this Build Your Own Case Study | Enhancing Patient Care for CAR T-Cell Therapy in NHL: Comprehensive Solutions for Your Community, learn from expert faculty about the most recent clinical updates and emerging real-world efficacy and safety data of CAR T-cell therapies in NHL. Build Your Own Case Study will guide participants through an interactive learning progression, as they go through two patient scenarios and make selections at critical decision points. Participants will be provided wit... |
|
|
Recent Developments in the Treatment of Clear Cell, Renal Cell Carcinoma: Essential Insights and Updates for the Healthcare Team
Target Audience
Oncology, Managed care and Specialty Pharmacists and Oncology Nurses/Nurse Practitioners
Program Overview
The goal of this educational initiative is to equip oncology nurse practitioners and nurses, as well as oncology, managed care, and specialty care pharmacists with the knowledge to apply findings from risk scoring systems used to stratify cases of clear cell renal cell carcinoma for treatment selection, differentiate among an expanding array of combination regimens con... |
|
|
Practice-Changing Advances in the Management of Hemophilia
STATEMENT OF NEED
Hemophilia is an inherited bleeding disorder in which the blood does not clot properly, causing affected individuals to experience spontaneous bleeding as well as bleeding after injuries or surgery. The 2 most common types are hemophilia A, caused by low levels of clotting factor VIII; and hemophilia B, caused by low levels of clotting factor IX. The standard treatment for hemophilia involves replacing the missing blood clotting factor by infusing commercially prepared facto... |
|
|
Podcast: Practice-Changing Advances in the Management of Hemophilia
STATEMENT OF NEED
Hemophilia is an inherited bleeding disorder in which the blood does not clot properly, causing affected individuals to experience spontaneous bleeding as well as bleeding after injuries or surgery. The 2 most common types are hemophilia A, caused by low levels of clotting factor VIII; and hemophilia B, caused by low levels of clotting factor IX. The standard treatment for hemophilia involves replacing the missing blood clotting factor by infusing commercially prepared facto... |
|
|
Acute Myeloid Leukemia: Targeting Key Clinical Issues for Oncology Nurses
The landscape of AML treatment is evolving, and newer targeted agents may improve outcomes for selected subgroups of patients. Activity goal considerations for the nurse/NP when participating in this activity:
Treatment decision making with incorporation of cytogenetic and molecular testing
Considerations in the care of a patient receiving therapy for AML related to nursing care and side effect management
Psychosocial considerations and resources for a patient with AML
Oncology nurses an... |
|
|
Keeping Up with the Evolving Treatment Landscape for Advanced/Metastatic Gastric/GEJ Cancer: Modeling Center of Excellence Practices
Are you optimally treating your patients with gastric/gastroesophageal junction (GEJ) cancers per the latest evidence on selection of therapies? Despite recent advancements in diagnosis of gastric/GEJ cancer, most cases are detected at advanced stages, resulting in poor outcomes. But advances have identified biomarkers that can offer more precise diagnostic and therapeutic approaches for gastric/GEJ cancer patients. In addition to HER2 and PD-L1 status, microsatellite instability (MSI) status... |
|
|
Internal Medicine Comprehensive Review and Update 2025 - LIVE STREAMING
Comprehensive, Evidence-Based Updates for Internal Medicine and Its Subspecialties
This program, the 65th annual Internal Medicine Update from the leading clinical faculty of Harvard Medical School and Massachusetts General Hospital, provides comprehensive, high-yield instruction to ensure clinicians are current with the latest evidence and best practices to optimize patient care.
This program covers the breadth of Internal Medicine subspecialties, including:
• Cardiovascular Medicine... |
|
|
Multiple Myeloma Care: Translating Evolving Practices to Oncology Nurses in Community Settings
The expansion of treatment options and strategies across the disease continuum is good news for patients who previously had few options; however, it can be a challenge for clinicians to stay up"to date in this very dynamic setting. |
|
|
Recognizing the Profound Impact on Quality of Life: Emerging Therapy Options for Patients with Myelofibrosis
In this on-demand activity, Recognizing the Profound Impact on Quality of Life: Emerging Therapy Options for Patients with Myelofibrosis, learn from expert faculty, Jeanne Palmer, MD and Jennifer Andres, APRN, FNP, MSN as they discuss Profound Impact on Quality of Life: Emerging Therapy Options for Patients with Myelofibrosis, to effectively identify how JAK inhibitors and emerging treatments for myelofibrosis (MF) can optimize clinical outcomes and patient quality of life (QOL).
Gain expe... |
|
|
Identifying Needs and Opportunities to Improve Clinical Outcomes in the Identification, Characterization, and Management of Low-Grade Serous Ovarian Cancer
Target Audience
This activity is designed to meet the educational needs of oncologists, obstetrician/gynecologists, gastroenterologists, and primary care physicians to ensure confidence in the diagnosis, characterization, and management of low-grade serous ovarian cancer, including through enrollment in ongoing clinical trials.
Program Overview
This enduring educational activity will provide insight into evidence-based approaches for clinical and pathological assessment of patients with d... |
|
|
Comprehensive Management of Von Hippel-Lindau Disease: Genetic and Oncological Perspectives
STATEMENT OF NEED
Von Hippel-Lindau disease (VHL) is an autosomal dominant disease in which germline pathogenic variants in the VHL gene predispose individuals to specific types of benign tumors, malignant tumors, and cysts in multiple organs, including clear cell renal cell carcinoma (RCC), renal cysts, central nervous system hemangioblastomas, retinal hemangioblastomas, pancreatic tumors and cysts, endolymphatic sac tumors, and cystadenomas of the epididymis and broad ligament (NIH, 2024). ... |
|
|
Establishing Frameworks for Precision Medicine in NTRK Fusion-Positive Advanced Solid Tumors
Despite significant advancements over the past decade, significant unmet needs persist for patients with NTRK-positive locally advanced or metastatic solid tumors. In addition, there is ongoing debate about the importance of testing for genomic alterations in rare cancers, or those that rarely occur in common cancers. However, evolving molecular testing procedures and emerging therapeutic options targeting NTRK fusions offer new pathways for the detection and treatment of these cancers. To he... |
|
|
Nuclear Medicine and Molecular Imaging Update
The Mid East Chapter of the Society of Nuclear Medicine and Molecular Imaging’s historic 50th Annual Conference presents nuclear medicine’s latest trends, advances and procedures. Adapted for the enduring material audience, Nuclear Medicine and Molecular Imaging Update features a dozen faculty members presenting this specialty’s impact on imaging, cardiology, neurology, endocrinology, oncology, rheumatology, pediatrics and much more. Practice enhancements and professional development w... |
|
|
Management of Metastatic Colorectal Cancer
Stacey Cohen, MD, explores the significance of molecular profiling and tumor markers in personalizing immunotherapy for metastatic colorectal cancer. She also delves into the evolving landscape of targeted therapies, discussing the nuances and considerations of different options to optimize patient outcomes. |
|
|
Optimizing Cancer Screening With MCED Technologies: From Science to Practical Application - Module 1
STATEMENT OF NEED
Approximately 2 million new cancer cases are expected in the United States in 2024, with an anticipated 611,720 deaths (ACS, 2024). Screening is associated with earlier stage at diagnosis and improved outcomes (Kim et al, 2011; Plumb et al, 2016). However, cancers that are not routinely screened for account for 78% of all cancer deaths in the United States, and even among cancers that do have standard tests, factors such as low awareness, lack of available facilities, and in... |
|
|
Optimizing Cancer Screening With MCED Technologies: From Science to Practical Application - Module 2
STATEMENT OF NEED
Approximately 2 million new cancer cases are expected in the United States in 2024, with an anticipated 611,720 deaths (ACS, 2024). Screening is associated with earlier stage at diagnosis and improved outcomes (Kim et al, 2011; Plumb et al, 2016). Multicancer early detection (MCED) is an emerging form of blood-based testing that utilizes cancer biomarkers in the blood to screen for multiple cancers simultaneously (ACS, 2024). Currently, numerous clinical trials are investiga... |
|
|
Optimizing Cancer Screening With MCED Technologies: From Science to Practical Application - Module 3
STATEMENT OF NEED
Approximately 2 million new cancer cases are expected in the United States in 2024, with an anticipated 611,720 deaths (ACS, 2024). Screening is associated with earlier stage at diagnosis and improved outcomes (Kim et al, 2011; Plumb et al, 2016). However, cancers that are not routinely screened for account for 78% of all cancer deaths in the United States (ACS, 2024; Pinsky & Berg, 2012; USPSTF, 2024). Multicancer early detection (MCED) is a novel form of blood-based ca... |
|
|
Podcast - Optimizing Cancer Screening With MCED Technologies: From Science to Practical Application - Module 1
STATEMENT OF NEED
Approximately 2 million new cancer cases are expected in the United States in 2024, with an anticipated 611,720 deaths (ACS, 2024). Screening is associated with earlier stage at diagnosis and improved outcomes (Kim et al, 2011; Plumb et al, 2016). However, cancers that are not routinely screened for account for 78% of all cancer deaths in the United States, and even among cancers that do have standard tests, factors such as low awareness, lack of available facilities, and in... |
|
|
Podcast - Optimizing Cancer Screening With MCED Technologies: From Science to Practical Application - Module 2
STATEMENT OF NEED
Approximately 2 million new cancer cases are expected in the United States in 2024, with an anticipated 611,720 deaths (ACS, 2024). Screening is associated with earlier stage at diagnosis and improved outcomes (Kim et al, 2011; Plumb et al, 2016). However, cancers that are not routinely screened for account for 78% of all cancer deaths in the United States, and even among cancers that do have standard tests, factors such as low awareness, lack of available facilities, and in... |
|
|
Podcast - Optimizing Cancer Screening With MCED Technologies: From Science to Practical Application - Module 3
STATEMENT OF NEED
Approximately 2 million new cancer cases are expected in the United States in 2024, with an anticipated 611,720 deaths (ACS, 2024). Screening is associated with earlier stage at diagnosis and improved outcomes (Kim et al, 2011; Plumb et al, 2016). However, cancers that are not routinely screened for account for 78% of all cancer deaths in the United States, and even among cancers that do have standard tests, factors such as low awareness, lack of available facilities, and in... |
|
|
Making The Call in Lower-Risk MDS Exploring Treatments That Improve Outcomes & Decrease Transfusion Burden
Myelodysplastic syndromes (MDSs) are among the most common hematologic malignancies and are characterized by their risk of progression to acute leukemia. Although patients with lower-risk MDS (LR-MDS) have longer life expectancies compared to those with high-risk disease, their disease course is not without challenges. In fact, symptoms related to anemia are very common in this population and lead to poor quality of life. Fortunately, therapies are now available to treat the anemia associated ... |
|
|
Recognizing and Confirming Potential ATTR in Your Patients
Target Audience
This activity is designed to meet the educational needs of physicians, allied health practitioners, and students interested in complex cardiovascular and thoracic conditions and those who care for patients with ATTR.
Program Overview
This activity will cover early diagnosis and intervention for transthyretin amyloidosis (ATTR), which is critical, yet does not occur, typically as a consequence of the rarity and heterogeneity of the disease and limited awareness on the part ... |
|
|
Bunion-Like Toes and Tumor Like Swellings " Recognize FOP and Improve Patient Outcomes in the Era of Disease Specific Therapy
Target Audience
This activity is designed to meet the educational needs of healthcare providers in pediatrics, primary care, oncology, surgery, radiology, acute care, emergency medicine, rheumatology, and infectious disease.
Program Overview
Bunion-like toes present at birth and tumor-like swellings in a young child are diagnostic signs of fibrodysplasia ossificans progressive (FOP), a disease with recent advances made in therapy. Upon completion of the course, learners should be able to ... |
|
|
Podcast: Multidisciplinary Task Force and Position Statement: Mitigating Disease Burden and Health Care Disparities in Relapsed/Refractory Multiple Myeloma
STATEMENT OF NEED
With the complex and rapidly evolving treatment landscape of multiple myeloma, it is vital that clinicians not only understand factors for informing selection of current and emerging combination and sequential therapeutic strategies, but also employ interdisciplinary strategies for reducing disparities in relapsed/refractory multiple myeloma care. The development of novel therapeutic options has significantly improved treatment outcomes for patients with relapsed/refractor... |
|
|
Defining the therapeutic algorithm in patients with HR positive breast cancer - United States
Target Audience
The initiative will target oncology clinicians in the US, Germany, Spain, Italy, and France, and specifically those actively involved in the treatment of breast cancer
Learning Objectives
Upon completion of this activity, participants should be better able to:
Assess the efficacy of new target therapy options in the management of patients with HR + early and metastatic BC with and implications for team-based and shared decision-making globall
Apply the most recent evid... |
|
|
Antibody Drug Conjugates (ADC) - United States
Target Audience
The initiative will target oncology clinicians in the US, Germany, Spain, Italy, and France, and specifically those actively involved in the treatment of breast cancer.
Learning Objectives
Upon completion of this activity, participants should be better able to:
Assess the efficacy of new target therapy options in the management of patients with HR + early and metastatic BC with and implications for team-based and shared decision-making globall
Apply the most recent evi... |
|
|
Treating SCLC in the Relapsed/Refractory Setting: Giving Patients a Voice About Second-Line Therapy
SCLC is aggressive in nature with a high recurrence rate following initial treatment and a propensity to become resistant to conventional therapies. Early detection is critical, but many patients are diagnosed at an advanced stage where prognosis is poor. Progress in the second-line setting offers new hope for improving patient outcomes, but the rapid pace at which these advances are occurring present challenges for effectively integrating novel therapies into patient care. In fact, research s... |
|
|
Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disorders: Addressing Unmet Needs with Emerging Therapies
In this Hematology Dialogues, Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disorders: Addressing Unmet Needs with Emerging Therapies, participants will learn about the epidemiology and burden of Epstein-Barr Virus-positive (EBV+) and post-transplant lymphoproliferative disorders (PTLD), differentiate between current and emerging prognostic scoring systems for EBV+ and PTLD to inform treatment decisions, and evaluate the latest clinical evidence of emerging treatment options ... |
|
|
Overcoming the Hurdles: Advances in the Management of Hemophilia
In this fast-moving, 1-hour accredited activity, Craig Kessler, MD, and Guy Young, MD, share their thoughts and experience with clotting factor concentrates, recombinant factor, factor VIII mimetics, rebalancing agents, and gene therapies. The safety and efficacy of late-phase investigational products are also discussed as these agents have the potential to address unmet needs and further transform patient care. |
|
|
HER3 in NSCLC " Navigating New Frontiers in Targeted Therapy
In patients with non-small cell lung cancer (NSCLC), human epidermal growth factor receptor 3 (HER3) is associated with both advanced disease and resistance to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI)"directed therapies. Although there are therapeutic options targeting EGFR (HER1) and HER2, the potential of HER3 as an anti-cancer target has been largely overlooked. Overexpression of HER3 in most patients with NSCLC positions it as an appealing therapeutic targ... |
|
|
Cracking the Code to Successful Stem Cell Mobilization in Multiple Myeloma
STATEMENT OF NEED
Multiple myeloma is the leading indication of autologous hematopoietic stem cell transplantation (ASCT) in hematologic malignancies, with high-dose therapy followed by ASCT representing a potentially curative treatment modality for eligible patients. Collecting peripheral blood stem cells (PBSCs) is an essential component of ASCT, and the collection of sufficient autologous PBSCs relies on the successful mobilization of hematopoietic stem cells from the bone marrow niche i... |
|
|
Prevention of Medical Errors in Nursing Practice
STATEMENT OF NEED
Medical errors are among the most common health-threatening mistakes that affect patient care, accounting for as many as 250,000 deaths per year in the United States (Makary & Daniel, 2016). Medical errors are considered a global problem; they affect as many as 20% of patients in primary and outpatient care and complicate a patient’s primary condition for which they needed medical attention (WHO, 2019). These errors can lead to adverse outcomes, such as increased mor... |
|
|
Toxicity Management and Symptom Control in Advanced RCC: Playbook Update
STATEMENT OF NEED
Each year, more than 430,000 cases of kidney cancer are diagnosed worldwide. Renal cell carcinoma (RCC), which includes clear cell, papillary, and chromophobe subtypes, is the most common form of kidney cancer. In recent years, the rise of immunotherapy and targeted therapy has contributed to a revolution in the treatment of RCC, with several novel agents and combinations granted approval. While these treatments demonstrate superior efficacy compared with previous standard... |
|
|
Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC.
Target Audience
The primary target audience for this activity are Academic and community-based physicians and team members, including hematologists, hematologic oncologists, medical oncologists, oncology nurses, NPs, PAs, and hematology-oncology pharmacists.
Statement of Need/Program Overview
Bispecific antibodies are relatively new agents in the treatment of multiple myeloma (MM). Because of this, many oncology clinicians are unfamiliar with their mechanism of action and the adverse even... |
|
|
Management of Cancer Pain: Current Guidelines
STATEMENT OF NEED
Patients with cancer often suffer from a range of symptoms that negatively impact their quality of life. Among the most significant of these symptoms is pain, which can be caused by surgery, radiation, chemotherapy, targeted therapy, diagnostic procedures, and/or supportive care measures. Between 20% and 50% of patients with cancer experience pain, including moderate-to-severe pain in approximately 80% of patients with advanced-stage cancer (NCI, 2023). Despite awareness a... |
|
|
Podcast: Multidisciplinary Task Force: Diagnosis and Management of Dedifferentiated Liposarcoma
STATEMENT OF NEED
Dedifferentiated liposarcoma (DDLPS) is an aggressive subtype of soft tissue sarcoma. Detection of MDM2 and/or CDK4 amplification distinguishes DDLPS from other types of undifferentiated sarcomas. Diagnosis of DDLPS remains challenging due to its complex karyotypes, quantitative genomic profiles, and pleomorphic pathological features (Nishio et al, 2021; Shen et al, 2022). Currently, surgical resection with or without radiation is the mainstay of treatment for localized di... |
|
|
Pathways to Precision: Integrating Genetic Counseling and Testing Into Cancer Care
STATEMENT OF NEED
Precision medicine is a cutting-edge approach that incorporates an individual’s genomic, environmental, and lifestyle information to deliver personalized healthcare. Genetic testing and counseling are crucial components of precision medicine, enabling clinicians to deliver the right care to the right patient at the right time (Turbitt et al, 2023). However, genetic testing often remains an untapped resource for patients who may benefit from genetic risk assessment and ca... |
|
|
Biosimilars in Osteoporosis: Highlights from the ASBMR
Biosimilars are large, complex molecules made from living organisms that are highly similar to their reference biologic and are administered in the same way, with the same strength and dosage, and clinically meaningful differences in safety, purity, and potency.
Incorporating biosimilars into the management of osteoporosis, known as a silent chronic disease responsible for 13 million fragility fractures worldwide, provide a more affordable version of osteoporosis medication, and an alternat... |
|
|
What’s New With HER2: Charting New Paths in NSCLC Care - Module 1: HER2 in NSCLC: Actionable Insights and Testing Recommendations
STATEMENT OF NEED
With the identification of oncogenic drivers and the development of targeted therapies, comprehensive molecular assessment has become a cornerstone of non"small cell lung cancer (NSCLC) management. Human epidermal growth factor receptor 2 (HER2) alterations, which include gene mutations, gene amplifications, and protein overexpression, are emerging therapeutic targets. While testing can be used to guide treatment decisions, the heterogeneity of HER2 alterations and th... |
|
|
What’s New With HER2: Charting New Paths in NSCLC Care - Module 2: Current and Emerging Treatments for HER2-Mutated NSCLC
STATEMENT OF NEED
In recent years, the discovery of oncogenic drivers and development of targeted therapies have transformed the treatment of advanced non"small cell lung cancer (NSCLC). Alterations in human epidermal growth factor receptor 2 (HER2), which include gene mutations, gene amplifications, and protein overexpression, are therapeutic targets. Several HER2-targeted therapies are under investigation in NSCLC and have demonstrated clinical benefit, with trastuzumab deruxtecan re... |
|
|
Podcast: What’s New With HER2: Charting New Paths in NSCLC Care - Module 1: HER2 in NSCLC: Actionable Insights and Testing Recommendations
STATEMENT OF NEED
With the identification of oncogenic drivers and the development of targeted therapies, comprehensive molecular assessment has become a cornerstone of non"small cell lung cancer (NSCLC) management. Human epidermal growth factor receptor 2 (HER2) alterations, which include gene mutations, gene amplifications, and protein overexpression, are emerging therapeutic targets. While testing can be used to guide treatment decisions, the heterogeneity of HER2 alterations and th... |
|
|
Podcast: What’s New With HER2: Charting New Paths in NSCLC Care - Module 2: Current and Emerging Treatments for HER2-Mutated NSCLC
STATEMENT OF NEED
In recent years, the discovery of oncogenic drivers and development of targeted therapies have transformed the treatment of advanced non"small cell lung cancer (NSCLC). Alterations in human epidermal growth factor receptor 2 (HER2), which include gene mutations, gene amplifications, and protein overexpression, are therapeutic targets. Several HER2-targeted therapies are under investigation in NSCLC and have demonstrated clinical benefit, with trastuzumab deruxtecan re... |
|
|
Improving Equity in Endometrial Cancer Care and Treatment: Accelerating Change to Improve Patient Outcomes in Rural and Underserved Communities
Target Audience
This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities.
Program Overview
In rural and underserved communities, disparities in incidence, treatment, and prognosis are pervasive among women with endometrial cancer. Key factors contributing to these gaps include limited access to oncology specialty care and lack of familiarity with current therapeut... |
|
|
Evolving Treatment Paradigms in HR+/HER2- Early Breast Cancer: Advancing Equitable Care in Rural and Underserved Communities
Target Audience
This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities.
Program Overview
Hormone receptor"positive, human epidermal growth factor receptor 2"negative (HR+/HER2-) breast cancer accounts for up to 70% of all breast cancer cases. In recent years, therapies such as CDK4/6 inhibitors, PARP inhibitors, and novel endocrine therapies have been ... |
|
|
Targeting the PI3K/AKT/PTEN Pathway for Treatment of Breast Cancer: Innovative Solutions for Equitable Care
Target Audience
This activity is designed specifically for oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities.
Program Overview
The PI3K/AKT/PTEN pathway has emerged as a key player in breast cancer development. Notably, up to 50% of patients with hormone receptor"positive, human epidermal growth factor receptor 2"negative (HR+/HER2-) breast cancer have actionable biomarkers within this pat... |
|
|
Management of Venous Thromboembolism in Ambulatory Patients With Cancer
STATEMENT OF NEED
Venous thromboembolism (VTE) is a common and potentially deadly complication in patients with cancer. The risk of cancer-related VTE has risen in the past 2 decades, with up to 15% of patients with cancer now experiencing VTE. Oncology nurses are ideally situated to assist in the identification of patients at risk for thrombotic events. This activity will discuss strategies for early identification of patients receiving outpatient (ambulatory) chemotherapy who are at high ... |
|
|
Cleveland Clinic Thyroid Expo (Online Streaming On Demand)
he Cleveland Clinic Thyroid Expo provides an updated review of the many multidisciplinary guidelines for the treatment of thyroid disorders. An expert faculty addresses topics such as molecular applications in thyroid neoplasia, cancer care, practical management tips and advances in laboratory testing. It focuses on new technologies in thyroid surgery, with a goal of increasing competence and clinical performance in managing routine and complex patient cases.
Worth 5 AMA PRA Category I C... |
|
|
Management of Venous Thromboembolism in Hospitalized Patients With Cancer
STATEMENT OF NEED
Venous thromboembolism (VTE) is a common and potentially deadly complication in patients with cancer, and hospitalized cancer patients are at an increased risk for both first-time and recurrent VTE. The National Comprehensive Cancer Network (NCCN) recommends VTE prophylaxis for all hospitalized cancer patients. Therefore, it is crucial for oncology nurses to be aware of risk factors, prevention, signs and symptoms, diagnosis, and management of VTE. This activity will discu... |
|
|
Management of Venous Thromboembolism in Hospitalized Patients With Cancer
TATEMENT OF NEED
Venous thromboembolism (VTE) is a common and potentially deadly complication in patients with cancer, and hospitalized cancer patients are at an increased risk for both first-time and recurrent VTE. The National Comprehensive Cancer Network (NCCN) recommends VTE prophylaxis for all hospitalized cancer patients. Therefore, it is crucial for oncology nurses to be aware of risk factors, prevention, signs and symptoms, diagnosis, and management of VTE. This activity will discuss ... |
|
|
Nursing Management of Oral Mucositis
STATEMENT OF NEED
Oral mucositis (OM) is the inflammation of oral mucosa resulting from cancer therapy and manifesting as atrophy, swelling, erythema, and ulceration (Oronsky et al, 2018). Patients with OM may experience moderate-to-severe pain, difficulty speaking, difficulty eating and drinking, and ulcerations characterized by submucosal hemorrhaging and infection (Bolton, 2021). Due to these crippling effects, OM is considered one of the most debilitating toxicities of cancer therapy (W... |
|